Director at Foghorn (NASDAQ: FHTX) receives 28,000 stock options grant

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Foghorn Therapeutics Inc. director Stuart Duty received a grant of stock options to buy 28,000 shares of Common Stock at an exercise price of $4.08 per share. The options vest in full on the first anniversary of the grant date, subject to his continued board service, and expire on June 23, 2036. Following this grant, Duty holds 28,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Duty Stuart

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to buy)	28,000	$4.08	$114K

Holdings After Transaction: Stock Options (Right to buy) — 28,000 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Options granted: 28,000 stock options Exercise price: $4.08 per share Underlying shares: 28,000 shares of Common Stock +2 more

5 metrics

Options granted 28,000 stock options Grant to director Stuart Duty

Exercise price $4.08 per share Stock option strike price

Underlying shares 28,000 shares of Common Stock Shares purchasable upon exercise

Expiration date June 23, 2036 Option term end

Post-grant derivative holdings 28,000 stock options Total options following transaction

Key Terms

Stock Options (Right to buy), Common Stock, Grant, award, or other acquisition, board of directors

4 terms

Stock Options (Right to buy) financial

"security_title: "Stock Options (Right to buy)""

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

board of directors financial

"subject to the reporting person's continued service on the board of directors"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 04:06 PM Accepted by SEC EDGAR 06/25/2026 - 04:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duty Stuart

(Last)

(First)

(Middle)

99 COOLIDGE AVENUE

STE 500

(Street)

WATERTOWN

MASSACHUSETTS

02472

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Foghorn Therapeutics Inc. [ FHTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (Right to buy)	$4.08	06/24/2026		A		28,000		⁽¹⁾	06/23/2036	Common Stock	28,000	$4.08	28,000	D

Explanation of Responses:

1. The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.

Remarks:

	/s/ Michael LaCascia, Attorney-in-Fact for Stuart Duty	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Foghorn Therapeutics (FHTX) report for Stuart Duty?

Foghorn Therapeutics reported that director Stuart Duty received a grant of stock options. He was awarded 28,000 options to acquire Common Stock at an exercise price of $4.08 per share as director compensation, according to a Form 4 insider filing.

How many stock options did Stuart Duty receive at Foghorn Therapeutics (FHTX)?

Stuart Duty received 28,000 stock options from Foghorn Therapeutics. These options give him the right to buy 28,000 shares of Common Stock at a fixed exercise price of $4.08 per share, subject to vesting conditions tied to continued board service.

What is the exercise price of Stuart Duty’s Foghorn Therapeutics (FHTX) options?

The exercise price of Stuart Duty’s stock options is $4.08 per share. This means he can purchase Foghorn Therapeutics Common Stock at $4.08 once the options vest, regardless of the market price at that time, until the options expire.

When do Stuart Duty’s Foghorn Therapeutics (FHTX) options vest?

Stuart Duty’s options vest in full on the first anniversary of the grant date. Vesting is conditional on his continued service on Foghorn Therapeutics’ board of directors, so he must remain a director through that one-year period to receive the full grant.

When do the stock options granted to Stuart Duty at Foghorn Therapeutics (FHTX) expire?

The stock options granted to Stuart Duty expire on June 23, 2036. After that expiration date, he can no longer exercise the right to buy Foghorn Therapeutics Common Stock at the fixed $4.08 exercise price under this specific option grant.

Is Stuart Duty’s Foghorn Therapeutics (FHTX) option grant a market purchase or compensation award?

The transaction is a compensation-related award, not a market purchase. The Form 4 describes it as a grant or award acquisition of stock options, issued in connection with his service on the Foghorn Therapeutics board of directors.